Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: A clinical trial study

Alireza Sadighi, Javid Safa, Amir-Mansour Vatankhah, Sona Ghorashi, Aida Aharilahagh, Sina Davari-Farid, Ourmaan Nezami-Nargabad, Mohammad Naghavi-Behzad, Reza Piri, Parinaz Pishahang, Savalan Babapoor-Farrokhran, Sanam Fakour, Nastaran Ghodratnezhad-Azar

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

BACKGROUND: Diabetic nephropathy (DN) is characterized by albuminuria, hypertension, and a progressive decline in glomerular filtration rate. The 3-hydroxy-3-methylglutaryl coenzyme A is a well-known agent that is active in lowering total plasma and low-density lipoprotein cholesterol (LDL-C) levels in cases with hypercholesterolemia. Hence, in this study, proteinuria changes at the beginning and after the withdrawal of lovastatin in patients with type 2 DN (T2DN) were studied.

MATERIALS AND METHODS: Lovastatin was administered for thirty male patients with T2DN and then was withdrawn. Twenty-four hours, urine creatinine and protein levels were determined.

RESULTS: The mean levels of total cholesterol and LDL-C were reduced without any change in the triglyceride (TG) level while the high-density lipoprotein cholesterol (HDL-C) level was increased. There was a reverse linear correlation between the changes in the level of HDL-C and the changes in the level of 24 h urine protein after 90 days of lovastatin therapy (P = 0.007, r = -0.484).

CONCLUSIONS: Short-term 3-month lovastatin therapy has no effect on proteinuria levels in patients with T2DN despite the antihyperlipidemic effects and reverse correlation of proteinuria with HDL-C.

OriginalsprogEngelsk
TidsskriftNigerian Medical Journal
Vol/bind57
Udgave nummer5
Sider (fra-til)253-259
ISSN0300-1652
DOI
StatusUdgivet - 12. nov. 2016
Udgivet eksterntJa

Fingeraftryk

Lovastatin
Diabetic Nephropathies
Clinical Trials
LDL Cholesterol
HDL Cholesterol
Urine
Albuminuria
Hypercholesterolemia
Glomerular Filtration Rate
Creatinine
Proteins
Clinical Studies

Citer dette

Sadighi, A., Safa, J., Vatankhah, A-M., Ghorashi, S., Aharilahagh, A., Davari-Farid, S., ... Ghodratnezhad-Azar, N. (2016). Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: A clinical trial study. Nigerian Medical Journal, 57(5), 253-259. https://doi.org/10.4103/0300-1652.190600
Sadighi, Alireza ; Safa, Javid ; Vatankhah, Amir-Mansour ; Ghorashi, Sona ; Aharilahagh, Aida ; Davari-Farid, Sina ; Nezami-Nargabad, Ourmaan ; Naghavi-Behzad, Mohammad ; Piri, Reza ; Pishahang, Parinaz ; Babapoor-Farrokhran, Savalan ; Fakour, Sanam ; Ghodratnezhad-Azar, Nastaran. / Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy : A clinical trial study. I: Nigerian Medical Journal. 2016 ; Bind 57, Nr. 5. s. 253-259.
@article{537b63247aa341a2a056176c5d6d76ea,
title = "Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: A clinical trial study",
abstract = "BACKGROUND: Diabetic nephropathy (DN) is characterized by albuminuria, hypertension, and a progressive decline in glomerular filtration rate. The 3-hydroxy-3-methylglutaryl coenzyme A is a well-known agent that is active in lowering total plasma and low-density lipoprotein cholesterol (LDL-C) levels in cases with hypercholesterolemia. Hence, in this study, proteinuria changes at the beginning and after the withdrawal of lovastatin in patients with type 2 DN (T2DN) were studied.MATERIALS AND METHODS: Lovastatin was administered for thirty male patients with T2DN and then was withdrawn. Twenty-four hours, urine creatinine and protein levels were determined.RESULTS: The mean levels of total cholesterol and LDL-C were reduced without any change in the triglyceride (TG) level while the high-density lipoprotein cholesterol (HDL-C) level was increased. There was a reverse linear correlation between the changes in the level of HDL-C and the changes in the level of 24 h urine protein after 90 days of lovastatin therapy (P = 0.007, r = -0.484).CONCLUSIONS: Short-term 3-month lovastatin therapy has no effect on proteinuria levels in patients with T2DN despite the antihyperlipidemic effects and reverse correlation of proteinuria with HDL-C.",
author = "Alireza Sadighi and Javid Safa and Amir-Mansour Vatankhah and Sona Ghorashi and Aida Aharilahagh and Sina Davari-Farid and Ourmaan Nezami-Nargabad and Mohammad Naghavi-Behzad and Reza Piri and Parinaz Pishahang and Savalan Babapoor-Farrokhran and Sanam Fakour and Nastaran Ghodratnezhad-Azar",
year = "2016",
month = "11",
day = "12",
doi = "10.4103/0300-1652.190600",
language = "English",
volume = "57",
pages = "253--259",
journal = "Nigerian Medical Journal",
issn = "0300-1652",
publisher = "Medknow Publications and Media Pvt. Ltd.",
number = "5",

}

Sadighi, A, Safa, J, Vatankhah, A-M, Ghorashi, S, Aharilahagh, A, Davari-Farid, S, Nezami-Nargabad, O, Naghavi-Behzad, M, Piri, R, Pishahang, P, Babapoor-Farrokhran, S, Fakour, S & Ghodratnezhad-Azar, N 2016, 'Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: A clinical trial study', Nigerian Medical Journal, bind 57, nr. 5, s. 253-259. https://doi.org/10.4103/0300-1652.190600

Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy : A clinical trial study. / Sadighi, Alireza; Safa, Javid; Vatankhah, Amir-Mansour; Ghorashi, Sona; Aharilahagh, Aida; Davari-Farid, Sina; Nezami-Nargabad, Ourmaan; Naghavi-Behzad, Mohammad; Piri, Reza; Pishahang, Parinaz; Babapoor-Farrokhran, Savalan; Fakour, Sanam; Ghodratnezhad-Azar, Nastaran.

I: Nigerian Medical Journal, Bind 57, Nr. 5, 12.11.2016, s. 253-259.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy

T2 - A clinical trial study

AU - Sadighi, Alireza

AU - Safa, Javid

AU - Vatankhah, Amir-Mansour

AU - Ghorashi, Sona

AU - Aharilahagh, Aida

AU - Davari-Farid, Sina

AU - Nezami-Nargabad, Ourmaan

AU - Naghavi-Behzad, Mohammad

AU - Piri, Reza

AU - Pishahang, Parinaz

AU - Babapoor-Farrokhran, Savalan

AU - Fakour, Sanam

AU - Ghodratnezhad-Azar, Nastaran

PY - 2016/11/12

Y1 - 2016/11/12

N2 - BACKGROUND: Diabetic nephropathy (DN) is characterized by albuminuria, hypertension, and a progressive decline in glomerular filtration rate. The 3-hydroxy-3-methylglutaryl coenzyme A is a well-known agent that is active in lowering total plasma and low-density lipoprotein cholesterol (LDL-C) levels in cases with hypercholesterolemia. Hence, in this study, proteinuria changes at the beginning and after the withdrawal of lovastatin in patients with type 2 DN (T2DN) were studied.MATERIALS AND METHODS: Lovastatin was administered for thirty male patients with T2DN and then was withdrawn. Twenty-four hours, urine creatinine and protein levels were determined.RESULTS: The mean levels of total cholesterol and LDL-C were reduced without any change in the triglyceride (TG) level while the high-density lipoprotein cholesterol (HDL-C) level was increased. There was a reverse linear correlation between the changes in the level of HDL-C and the changes in the level of 24 h urine protein after 90 days of lovastatin therapy (P = 0.007, r = -0.484).CONCLUSIONS: Short-term 3-month lovastatin therapy has no effect on proteinuria levels in patients with T2DN despite the antihyperlipidemic effects and reverse correlation of proteinuria with HDL-C.

AB - BACKGROUND: Diabetic nephropathy (DN) is characterized by albuminuria, hypertension, and a progressive decline in glomerular filtration rate. The 3-hydroxy-3-methylglutaryl coenzyme A is a well-known agent that is active in lowering total plasma and low-density lipoprotein cholesterol (LDL-C) levels in cases with hypercholesterolemia. Hence, in this study, proteinuria changes at the beginning and after the withdrawal of lovastatin in patients with type 2 DN (T2DN) were studied.MATERIALS AND METHODS: Lovastatin was administered for thirty male patients with T2DN and then was withdrawn. Twenty-four hours, urine creatinine and protein levels were determined.RESULTS: The mean levels of total cholesterol and LDL-C were reduced without any change in the triglyceride (TG) level while the high-density lipoprotein cholesterol (HDL-C) level was increased. There was a reverse linear correlation between the changes in the level of HDL-C and the changes in the level of 24 h urine protein after 90 days of lovastatin therapy (P = 0.007, r = -0.484).CONCLUSIONS: Short-term 3-month lovastatin therapy has no effect on proteinuria levels in patients with T2DN despite the antihyperlipidemic effects and reverse correlation of proteinuria with HDL-C.

U2 - 10.4103/0300-1652.190600

DO - 10.4103/0300-1652.190600

M3 - Journal article

C2 - 27833243

VL - 57

SP - 253

EP - 259

JO - Nigerian Medical Journal

JF - Nigerian Medical Journal

SN - 0300-1652

IS - 5

ER -